Clinical Trial Update: Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of zimberelimab plus domvanalimab in stomach and gastroesophageal junction adenocarcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Junction Adenocarcinoma
• Stomach Adenocarcinoma

Drugs mentioned

• Domvanalimab (domvanalimab)
• Zimberelimab (zimberelimab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Adenocarcinoma Stomach, Adenocarcinoma Gastroesophageal Junction | Phase 2 | Status: WITHDRAWN